Market Place
Sourcing Support
Sangamo Therapeutics Showcases Advances At ASGCT Conference
30 Apr 2026 //
GLOBENEWSWIRE
Sangamo Reports Business Highlights & 2025 Financial Results
30 Mar 2026 //
GLOBENEWSWIRE
Sangamo Advances BLA Submission For ST-920 In Fabry Disease
09 Mar 2026 //
GLOBENEWSWIRE
Sangamo Begins BLA Submission For ST-920 In Fabry Disease
18 Dec 2025 //
GLOBENEWSWIRE
FDA Fast-Tracks Sangamo`s ST-503 for Small Fiber Neuropathy
02 Dec 2025 //
GLOBENEWSWIRE
FDA accepts Sangamo`s rolling BLA submission for Fabry
22 Nov 2025 //
PRESS RELEASE
Sangamo Pharma Highlights Q3 2025 Results
06 Nov 2025 //
GLOBENEWSWIRE
Sangamo Therapeutics Reports Q2 2025 Financial Results
07 Aug 2025 //
GLOBENEWSWIRE
Sangamo Reports Positive Topline STAAR Fabry Trial Results
24 Jun 2025 //
BUSINESSWIRE
Sangamo Therapeutics Postpones Q1 2025 Call to Later Same Day
12 May 2025 //
BUSINESSWIRE
Sangamo Hits Milestones Toward ST-920 BLA In Fabry Diseases
06 May 2025 //
BUSINESSWIRE
Sangamo to Present Neurology Pipeline Advances at ASGCT
28 Apr 2025 //
BUSINESSWIRE
Sangamo Therapeutics, Lilly Capsid License for CNS Diseases
03 Apr 2025 //
BUSINESSWIRE
Sangamo Therapeutics Announces Q4 2024 Earnings Call and Investor
06 Mar 2025 //
BUSINESSWIRE
Sangamo Updates Phase 1/2 STAAR Study Data in Fabry Disease
06 Feb 2025 //
BUSINESSWIRE
Sangamo’s Stock Plummets as Pfizer Axes Hemophilia Gene Therapy
03 Jan 2025 //
BIOSPACE
Sangamo shares plunge after Pfizer ends hemophilia A therapy deal
01 Jan 2025 //
REUTERS
Astellas & Sangamo License Capsid for Neurological Genomic Medicine
19 Dec 2024 //
PR NEWSWIRE
Sangamo & Astellas Announce Capsid License for Gene Therapies
19 Dec 2024 //
BUSINESSWIRE
Astellas pays Sangamo $20M to boost neurological gene therapies
19 Dec 2024 //
FIERCE BIOTECH
Sangamo slashes time to market for Fabry gene therapy
23 Oct 2024 //
FIERCE BIOTECH
Sangamo secures $50M upfront in neurodegenerative pact with Roche`s Genentech
07 Aug 2024 //
FEIRCE BIOTECH
Sangamo secures $50M upfront in neurodegenerative pact with Roche`s Genentech
06 Aug 2024 //
FIERCE BIOTECH
Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
30 Jul 2024 //
BUSINESSWIRE
Sangamo`s Neuro Gene Editing, Delivery Platforms At ASGCT
22 Apr 2024 //
BUSINESSWIRE
Lilly taps Sangamo to explore AAV capsids for neurological targets
18 Jul 2023 //
PRESS RELEASE
Sangamo Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec
22 May 2023 //
BUSINESSWIRE
Sangamo scraps public offering ‘after evaluating market conditions’
03 Mar 2023 //
ENDPTS
Sangamo, joining other rivals, shelves sickle cell therapy
23 Feb 2023 //
FIERCE BIOTECH
